Pemigatinib is used for treating cholangiocarcinoma and myeloid/lymphoid neoplasms with specific genetic rearrangements in patients who have not responded to previous treatments. It was first introduced by Incyte Corp in its drug Pemazyre on Apr 17, 2020.

Pemigatinib Patents

Given below is the list of patents protecting Pemigatinib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Pemazyre	US10131667	Substituted tricyclic compounds as FGFR inhibitors	Jun 12, 2033	Incyte Corp
Pemazyre	US11466004	Solid forms of an FGFR inhibitor and processes for preparing the same	May 03, 2039	Incyte Corp
Pemazyre	US11628162	Methods of treating cancer with an FGFR inhibitor	Aug 30, 2040	Incyte Corp
Pemazyre	US9611267	Substituted tricyclic compounds as FGFR inhibitors	Jan 30, 2035	Incyte Corp

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳